{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16"}]}],"title":"Neither CMV or EBV"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9"}]}],"title":"CMV reactivation only"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"EBV only"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Both CMV and EBV"}],"denoms":[{"counts":[{"groupId":"OG000","value":"32"}],"units":"Participants"}],"description":"Participants were monitored throughout the trial (median of 28 months) for various infections/complications.","groups":[{"description":"All patients were analyzed as a single population. Stratification by conditioning regimen was not done.","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Median Follow Up: 28 months (Range: 1-49 months)","title":"Occurence of Infections Including Cytomegalovirus and Epstein-Barr Virus Reactivation","type":"SECONDARY","unitOfMeasure":"participants"}